diarrhea/breast neoplasms

Koblingen er lagret på utklippstavlen

Velg sorteringstype

Side 1 fra 991 resultater

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

The APHINITY (BIG 4-11) study showed that pertuzumab significantly improved the rates of invasive disease-free survival among patients with human epidermal growth factor receptor 2 (HER2)-positive, operable breast cancer when added to adjuvant trastuzumab and chemotherapy. Because

Inflammatory breast cancer with refractory diarrhea: a case report.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Excessive amounts of vasoactive intestinal polypeptide (VIP) cause a special clinical syndrome characterized by secretory diarrhea, hypokalemia and dehydration. A careful clinical workup of a 62-year-old female admitted for refractory diarrhea revealed a neglected inflammatory right breast ductal

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OBJECTIVE To inform lumretuzumab and pertuzumab dose modifications in order to decrease the incidence, severity, and duration of the diarrhea events in metastatic breast cancer patients treated with a combination therapy of lumretuzumab (anti-HER3) in combination with pertuzumab (anti-HER2) and

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OBJECTIVE Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel and trastuzumab (PT) is feasible. Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer. We conducted a pilot study of dose-dense AC followed by

Chronic diarrhea due to metastatic breast cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

We report the case of a patient with chronic diarrhea due to infiltrative cancer to the colon from the breast. A 49-year-old woman with a history of metastatic breast cancer to the bones was admitted to hospital with 4 weeks of watery diarrhea. Computed tomography (CT) scan of the abdomen showed

Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: A comparison of trials to actual practice.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Although landmark trials in the metastatic (CLEOPATRA) and neo-adjuvant (NeoSphere; TRYPHAENA) settings identified all-grade diarrhea as a pertuzumab-associated adverse event, it was not classified as dose-limiting. In actual practice, diarrhea is often a reason for treatment

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and

HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Approximately 40% to 80% of patients receiving pertuzumab-directed therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop chemotherapy-induced diarrhea (CID). Loperamide and octreotide are frequently used to treat CID after diarrhea occurs, but neither is

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Lapatinib and capecitabine have been widely used in the therapy of breast cancer. However, long-term use of lapatinib and capecitabine often causes the most common side effect diarrhea, which limit the medicine use. Fructus mume (F. mume) has been proved to be effective to treat chronic diarrhea

Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC). However, moderate to severe diarrhea and rash (≥ grade 2) are problematic dose limiting toxicities. Since risk may vary over the course of therapy, we developed repeated measures models to

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine: rule of thumb in prediction studies.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Tidligere
1
2
3
4
5
6
...
66
67
Neste

Bli med på
facebooksiden vår

Herbal & Natural Medicine

Den mest komplette databasen med medisinske urter støttet av vitenskap

Fungerer på 55 språk
Urtekurer støttet av vitenskap
Urtegjenkjenning etter bilde
Interaktivt GPS-kart - merk urter på stedet (kommer snart)
Les vitenskapelige publikasjoner relatert til søket ditt
Søk medisinske urter etter deres effekter
Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter

Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning

diarrhea/breast neoplasms

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Inflammatory breast cancer with refractory diarrhea: a case report.

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Chronic diarrhea due to metastatic breast cancer.

Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: A comparison of trials to actual practice.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine.

Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Considerations When Initiating Neratinib for Breast Cancer: How to Prevent and Treat Diarrhea.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine: rule of thumb in prediction studies.

Den mest komplette databasen med medisinske urter støttet av vitenskap